Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Erik Magnus Ohman"'
Autor:
Adam D. DeVore, Eric Yow, Mitchell W. Krucoff, Matthew W. Sherwood, Linda K. Shaw, Karen Chiswell, Christopher M. O'Connor, Erik Magnus Ohman, Eric J. Velazquez
Publikováno v:
ESC Heart Failure, Vol 6, Iss 6, Pp 1233-1242 (2019)
Abstract Aims We sought to better understand the role of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and moderate or severe left ventricular systolic dysfunction. Methods and results Using data from
Externí odkaz:
https://doaj.org/article/ba9f263e2ec24d488983676b1ca9cdc3
Autor:
Mitchell W. Krucoff, Eric J. Velazquez, Adam D. DeVore, Karen Chiswell, Erik Magnus Ohman, Matthew W. Sherwood, Linda K. Shaw, Eric Yow, Christopher M. O'Connor
Publikováno v:
ESC Heart Failure, Vol 6, Iss 6, Pp 1233-1242 (2019)
ESC Heart Failure
ESC Heart Failure
Aims We sought to better understand the role of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and moderate or severe left ventricular systolic dysfunction. Methods and results Using data from the Duke
Autor:
Aakriti Gupta, Saurav Chatterjee, Mahesh V. Madhavan, Harlan M. Krumholz, Umberto Benedetto, John R. Burton, Charles Michael Gibson, Seng C. You, Caroline Der Nigoghossian, Gregg W. Stone, Dominic P. Francese, Dominick J. Angiolillo, Erik Magnus Ohman, Philippe Gabriel Steg, Aaron Crowley, Behnood Bikdeli, Adnan Kastrati, Tullio Palmerini, Giuseppe Biondi-Zoccai, Nicholas J. Varunok, Björn Redfors
Publikováno v:
Minerva Cardiology and Angiology.
INTRODUCTION The optimal choice of oral P2Y 12 receptor inhibitors has the potential to significantly influence outcomes. We seek to compare the safety and efficacy of the three most commonly used oral P2Y 12 receptor inhibitors (clopidogrel, prasugr
Autor:
Jennifer Rymer, Deepak L. Bhatt, Dominick J. Angiolillo, Miguel A. Diaz, Kirk N. Garratt, Ron Waksman, Laura Edwards, Gudaye Tasissa, Khalid Salahuddin, Hijrah El-Sabae, Carmen Dell’Anna, Linda Davidson-Ray, Jeffrey B. Washam, Erik Magnus Ohman, Tracy Wang
Publikováno v:
Journal of the American College of Cardiology. 79:1063
Autor:
Philippe Gabriel Steg, Shamir R. Mehta, Paul A. Gurbel, Roxana Mehran, Steven O. Marx, Samin K. Sharma, Dominick J. Angiolillo, Stuart J. Pocock, Johny Nicolas, Ran Kornowski, Timothy D. Henry, Richard Shlofmitz, Yaling Han, Gennaro Sardella, Dariusz Dudek, Upendra Kaul, Mitchell W. Krucoff, David J. Cohen, Jin Yu Cha, Timothy Collier, Robert J. Gil, Keith G. Oldroyd, George Dangas, Adnan Kastrati, Samantha Sartori, Charles Michael Gibson, Javier Escaned, David J. Moliterno, Vijay Kunadian, Erik Magnus Ohman, Giora Weisz, Christian W. Hamm, Vladimír Džavík, Usman Baber, Carlo Briguori, Bernhard Witzenbichler, Kurt Huber
Aims The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) amo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17cbb5eca3f7a9e3da99700d2731d549
http://hdl.handle.net/11573/1498497
http://hdl.handle.net/11573/1498497
Autor:
Stefan James, John H. Alexander, Karen S. Pieper, Matthew T. Roe, Daniel Wojdyla, Pierluigi Tricoci, Lars Wallentin, Kenneth W. Mahaffey, Manesh R. Patel, Erik Magnus Ohman, William S Jones, Renato D. Lopes, Taku Inohara, Sreekanth Vemulapalli
Publikováno v:
American Heart Journal. 201:25-32
Patients with peripheral artery disease (PAD) are known to have an increased risk of ischemic cardiovascular events. However, the influence of concomitant PAD on first and subsequent recurrent ischemic events after an acute coronary syndrome (ACS) re
Autor:
Robert A. Harrington, Erik Magnus Ohman, Kenneth W. Mahaffey, Megan L. Neely, Stefan James, Robert M. Clare, Pierluigi Tricoci, Renato D. Lopes, Connie N. Hess, Matthew T. Roe, Harvey D. White, Claes Held, Keith A.A. Fox, Lars Wallentin, Paul W. Armstrong, John H. Alexander
Publikováno v:
American Heart Journal. 187:194-203
Objective Acute coronary syndrome (ACS) trials typically use a composite primary outcome (myocardial infarction [MI], stroke, or cardiovascular death), but differential patient characteristics, timing, and consequences associated with individual comp
Autor:
William S Jones, T. A Girton, Erik Magnus Ohman, Anna E Mall, Bradi B. Granger, Kevin Yardley, Paige Rossman
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 12
Background: Patient centeredness is an essential component of high-quality care, yet little is published regarding the patient experience during procedures performed in the cardiac catheterization lab. Available literature focuses on the safe deliver
Autor:
William W. O'Neill, Akshay Khandelwal, Theodore Schreiber, Simon R. Dixon, Brian P. O'Neill, Navin K. Kapur, Mauricio G. Cohen, Erik Magnus Ohman, Cindy L. Grines, Mir B Basir
Publikováno v:
The American journal of cardiology. 123(8)
The outcomes for patients transferred with cardiogenic shock and later treated with revascularization and Impella support have not previously been studied. To evaluate these outcomes, patients in cardiogenic shock were recruited from the catheter-bas
Autor:
Kenneth W. Mahaffey, John H. Alexander, Karen P. Alexander, Matthew T. Roe, Kathleen M. Trollinger, Patrícia O. Guimarães, Claes Held, Chiara Melloni, Ghazala Haque, Stefan James, Erik Magnus Ohman, André Zimerman, Pierluigi Tricoci, Renato D. Lopes, Brian Tinga, Karen S. Pieper, Amanda Stebbins
Publikováno v:
American Heart Journal. 174:60-67
Background Adverse event collection in randomized clinical trials establishes drug safety. Although costly and regulated, it is rarely studied. Methods Adverse event data from 4 clinical trials (APPRAISE-2, PLATO, TRACER, TRILOGY ACS) comprising 48,1